View Older Stories View More Recent Stories

Mar 1, 2023 08:03AM PDS Biotechnology (PDSB) Announces the Publication of PDS0301 Study
Mar 1, 2023 08:00AM PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal
Feb 27, 2023 08:00AM PDS Biotechnology (PDSB) Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
Feb 27, 2023 08:00AM PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
Feb 16, 2023 08:00AM PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
Feb 8, 2023 04:01PM PDS Biotech (PDSB) Announces Publication of Preclinical Infectimune Based Vaccine Studies
Feb 8, 2023 04:00PM PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
Feb 6, 2023 08:00AM PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress
Jan 26, 2023 08:00AM PDS Biotech Announces Participation in the Channelchek Takeaway Series
Jan 13, 2023 08:00AM PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference
Jan 3, 2023 07:05AM PDS Biotechnology (PDSB) Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA
Jan 3, 2023 07:00AM PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
Dec 28, 2022 08:00AM PDS Biotechnology (PDSB) Reports Expanded Interim Phase 2 Data for PDS0101-based Triple Combination Therapy
Dec 28, 2022 08:00AM PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months
Dec 15, 2022 08:00AM PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
Nov 21, 2022 08:00AM PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress
Nov 14, 2022 07:30AM PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 14, 2022 07:09AM PDS Biotechnology (PDSB) Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
Nov 14, 2022 07:00AM PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
Nov 7, 2022 08:00AM PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)
Oct 31, 2022 08:00AM PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results
Oct 27, 2022 08:00AM PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
Oct 25, 2022 08:00AM PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference
Oct 19, 2022 08:00AM PDS Biotech to Present at the LD Micro Main Event XV
Oct 17, 2022 08:03AM PDS Biotechnology (PDSB) Announces Abstract Demonstrating Versatility of the Versamune
Oct 17, 2022 08:00AM PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy
Oct 12, 2022 08:00AM PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022
Oct 11, 2022 08:01AM PDS Biotechnology (PDSB) Announces Expanded Interim Data in PDS0101
Oct 11, 2022 08:00AM PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers
Oct 7, 2022 04:01PM PDS Biotech Reports An Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Oct 5, 2022 08:00AM PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022
Oct 3, 2022 08:00AM PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA®
Sep 23, 2022 04:05PM PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 22, 2022 08:00AM PDS Biotech to Participate at Cantor Fitzgerald’s Oncology & HemOnc Conference
Sep 21, 2022 08:00AM PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers
Sep 6, 2022 08:00AM PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference
Sep 6, 2022 08:00AM PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference
Aug 24, 2022 04:01PM PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
Aug 8, 2022 07:00AM PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 4, 2022 08:04AM PDS Biotechnology (PDSB) Announces Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications
Aug 4, 2022 08:00AM PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications
Aug 2, 2022 08:00AM PDS Biotech to Participate at BTIG Biotechnology Conference 2022
Jul 26, 2022 08:00AM PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2022 Financial Results
Jul 14, 2022 08:04AM PDS Biotechnology (PDSB) to Present Flu Vaccine Preclinical Data
Jul 14, 2022 08:00AM PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting
Jun 3, 2022 08:00AM PDS Biotechnology Appoints Spencer Brown as Senior Vice President, General Counsel
Jun 2, 2022 08:59AM PDS Biotechnology (PDSB) Granted FDA Fast Track Designation for Lead Candidate PDS0101
Jun 2, 2022 08:00AM PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101
May 31, 2022 08:11AM PDS Biotechnology (PDSB) Announces Expansion of its VERSATILE-002 Clinical Trial into Europe
May 31, 2022 08:00AM PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe
View More Recent Stories View Older Stories